{"id":"vx-770","safety":{"commonSideEffects":[{"rate":"approximately 20-30%","effect":"Headache"},{"rate":"approximately 15-25%","effect":"Upper respiratory tract infection"},{"rate":"approximately 10-15%","effect":"Oropharyngeal pain"},{"rate":"approximately 10-15%","effect":"Diarrhea"},{"rate":"approximately 5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"VX-770 binds to CFTR and enhances its function by increasing the time the channel spends in the open state, allowing greater chloride ion transport across epithelial cell membranes. This mechanism is particularly effective for cystic fibrosis patients with gating mutations (such as G551D) where the CFTR protein is present but dysfunctional. By restoring chloride channel function, VX-770 reduces the viscosity of airway secretions and improves lung function.","oneSentence":"VX-770 is a CFTR potentiator that increases the opening probability and duration of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel at the cell surface.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:57.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis with G551D-CFTR mutation"},{"name":"Cystic fibrosis with other gating mutations"}]},"trialDetails":[{"nctId":"NCT02194881","phase":"","title":"Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-10","conditions":"Cystic Fibrosis","enrollment":57},{"nctId":"NCT05668741","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-02-27","conditions":"Cystic Fibrosis","enrollment":39},{"nctId":"NCT03894657","phase":"NA","title":"Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-12-18","conditions":"Cystic Fibrosis, Homozygous F508del Mutation","enrollment":91},{"nctId":"NCT05153317","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-01-17","conditions":"Cystic Fibrosis","enrollment":71},{"nctId":"NCT07443436","phase":"PHASE2","title":"Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-10-01","conditions":"Interstitial Lung Disease","enrollment":30},{"nctId":"NCT04732910","phase":"","title":"Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2018-07-01","conditions":"Cystic Fibrosis","enrollment":500},{"nctId":"NCT07303621","phase":"","title":"Population Pharmacokinetics of Elexacaftor-tezacaftor-ivacaftor in a Paediatric Population","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-02-09","conditions":"Cystic Fibrosis (CF)","enrollment":150},{"nctId":"NCT05743946","phase":"PHASE4","title":"Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-04-18","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":32},{"nctId":"NCT03587961","phase":"EARLY_PHASE1","title":"Personalized Theratyping Trial","status":"RECRUITING","sponsor":"George Solomon","startDate":"2019-08-01","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT07363304","phase":"","title":"Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.","status":"RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2025-12-02","conditions":"Cystic Fibrosis (CF)","enrollment":150},{"nctId":"NCT05331183","phase":"PHASE3","title":"Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-11-23","conditions":"Cystic Fibrosis","enrollment":297},{"nctId":"NCT06237335","phase":"PHASE2","title":"A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF","status":"RECRUITING","sponsor":"ReCode Therapeutics","startDate":"2024-02-01","conditions":"Cystic Fibrosis","enrollment":192},{"nctId":"NCT07102043","phase":"","title":"Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Cystic Fibrosis Related Diabetes","enrollment":30},{"nctId":"NCT07314229","phase":"NA","title":"Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2026-01-01","conditions":"Cystic Fibrosis (CF), Mucoviscidosis","enrollment":130},{"nctId":"NCT03475381","phase":"","title":"Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-01-22","conditions":"Cystic Fibrosis","enrollment":852},{"nctId":"NCT06457451","phase":"NA","title":"Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial","status":"RECRUITING","sponsor":"University Hospital, Tours","startDate":"2024-11-25","conditions":"Cystic Fibrosis","enrollment":100},{"nctId":"NCT06507956","phase":"","title":"Physical Activity Profile and Sedentary Behaviour in Adults With Cystic Fibrosis","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-09-17","conditions":"Cystic Fibrosis","enrollment":270},{"nctId":"NCT03659214","phase":"","title":"Impact of the Introduction of ORKAMBI on Anxiety, Depression, Quality of Life and Adherence of Adolescents and Young Adults","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-12-01","conditions":"Cystic Fibrosis","enrollment":19},{"nctId":"NCT06683092","phase":"","title":"Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2025-05-01","conditions":"Cystic Fibrosis","enrollment":200},{"nctId":"NCT04613128","phase":"","title":"The PROMISE Pediatric Study 6 to 11 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nicole Hamblett","startDate":"2021-06-11","conditions":"Cystic Fibrosis, Cystic Fibrosis in Children","enrollment":180},{"nctId":"NCT05882357","phase":"PHASE3","title":"Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-06-27","conditions":"Cystic Fibrosis","enrollment":70},{"nctId":"NCT06460506","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-11-21","conditions":"Cystic Fibrosis","enrollment":50},{"nctId":"NCT06191640","phase":"","title":"Sinus Disease in Young Children With Cystic Fibrosis","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2023-04-12","conditions":"Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis)","enrollment":80},{"nctId":"NCT04969224","phase":"PHASE3","title":"A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-12","conditions":"Cystic Fibrosis","enrollment":82},{"nctId":"NCT03525574","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-10-09","conditions":"Cystic Fibrosis","enrollment":507},{"nctId":"NCT02070744","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2014-03","conditions":"Cystic Fibrosis","enrollment":40},{"nctId":"NCT04970225","phase":"NA","title":"Cystic Fibrosis Blood Neutrophils","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-07-08","conditions":"Cystic Fibrosis","enrollment":47},{"nctId":"NCT03506061","phase":"PHASE2","title":"Trikafta in Cystic Fibrosis Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-09-04","conditions":"Cystic Fibrosis","enrollment":42},{"nctId":"NCT07148739","phase":"PHASE4","title":"Ensuring Access to Optimal Therapy in CF: The ENACT Study","status":"RECRUITING","sponsor":"Arkansas Children's Hospital Research Institute","startDate":"2025-06-10","conditions":"Cystic Fibrosis (CF)","enrollment":95},{"nctId":"NCT05752019","phase":"","title":"TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-03-21","conditions":"Cystic Fibrosis, Lung Inflammation, Lung Infection","enrollment":103},{"nctId":"NCT07022327","phase":"","title":"Ivacaftor Impact in an Adolescent Without a Cystic Fibrosis-Associated CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Mutation for Chronic Pancreatitis: Single-Patient Study Tracking Flare Frequency and Health Data Compared to Historical Records.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mission: Cure","startDate":"2025-05-06","conditions":"Chronic Pancreatitis","enrollment":1},{"nctId":"NCT04183790","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-02-17","conditions":"Cystic Fibrosis","enrollment":64},{"nctId":"NCT06331000","phase":"","title":"Effect of One Year Elexacaftor-tezacaftor-ivacaftor Treatment","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-04-08","conditions":"Cystic Fibrosis","enrollment":184},{"nctId":"NCT04581408","phase":"PHASE2","title":"Mutation-specific Therapy for the Long QT Syndrome","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2021-06-15","conditions":"Long QT Syndrome","enrollment":16},{"nctId":"NCT02997020","phase":"","title":"Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (EDSPD Protocol)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2017-05-18","conditions":"CRS","enrollment":30},{"nctId":"NCT03624101","phase":"PHASE4","title":"Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2018-12-01","conditions":"Cystic Fibrosis","enrollment":1},{"nctId":"NCT03439865","phase":"EARLY_PHASE1","title":"Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2019-05-02","conditions":"Chronic Rhinosinusitis (Diagnosis)","enrollment":20},{"nctId":"NCT05279040","phase":"","title":"Trikafta Exercise Study in Cystic Fibrosis","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-11-10","conditions":"Cystic Fibrosis, Lung Diseases","enrollment":20},{"nctId":"NCT05519020","phase":"","title":"Inhaled Therapy Adherence and Outcomes to Kaftrio in Cystic Fibrosis","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2022-07-27","conditions":"Cystic Fibrosis","enrollment":1385},{"nctId":"NCT05818319","phase":"NA","title":"Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/tezacaftor/ivacaftor in Urine After a Short Pause of Therapy","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2023-06-01","conditions":"Cystic Fibrosis (CF), CFTR Gene Mutation","enrollment":30},{"nctId":"NCT04038047","phase":"","title":"A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function","status":"COMPLETED","sponsor":"Nicole Hamblett","startDate":"2019-10-22","conditions":"Cystic Fibrosis","enrollment":490},{"nctId":"NCT03085485","phase":"PHASE2","title":"The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2017-03-16","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Bronchitis","enrollment":40},{"nctId":"NCT03277196","phase":"PHASE3","title":"A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-08-16","conditions":"Cystic Fibrosis","enrollment":86},{"nctId":"NCT05033080","phase":"PHASE3","title":"A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-09-14","conditions":"Cystic Fibrosis","enrollment":435},{"nctId":"NCT06370962","phase":"","title":"Circadian Rhythm Disorders in Children With Cystic Fibrosis Under CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Modulators","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-04-29","conditions":"Cystic Fibrosis","enrollment":180},{"nctId":"NCT04235140","phase":"PHASE3","title":"Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-02-24","conditions":"Cystic Fibrosis","enrollment":52},{"nctId":"NCT04509050","phase":"","title":"Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children","status":"RECRUITING","sponsor":"Sonya Heltshe","startDate":"2020-11-18","conditions":"Cystic Fibrosis","enrollment":210},{"nctId":"NCT04840862","phase":"PHASE4","title":"Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2022-05-09","conditions":"Drug Drug Interaction","enrollment":6},{"nctId":"NCT05274269","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-05-09","conditions":"Cystic Fibrosis","enrollment":307},{"nctId":"NCT05076149","phase":"PHASE3","title":"A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-27","conditions":"Cystic Fibrosis","enrollment":597},{"nctId":"NCT06284577","phase":"NA","title":"Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-01-02","conditions":"Cystic Fibrosis in Children","enrollment":40},{"nctId":"NCT04618185","phase":"","title":"Gut Imaging for Function & Transit in CF - GIFT-CF 3","status":"COMPLETED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2020-10-21","conditions":"Cystic Fibrosis","enrollment":24},{"nctId":"NCT04545515","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-11","conditions":"Cystic Fibrosis","enrollment":120},{"nctId":"NCT04602468","phase":"PHASE4","title":"Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Royal College of Surgeons, Ireland","startDate":"2020-09-03","conditions":"Cystic Fibrosis, Cystic Fibrosis Liver Disease, Cystic Fibrosis in Children","enrollment":237},{"nctId":"NCT03537651","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-04-25","conditions":"Cystic Fibrosis","enrollment":130},{"nctId":"NCT02965326","phase":"NA","title":"Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients","status":"RECRUITING","sponsor":"Hôpital Necker-Enfants Malades","startDate":"2016-05","conditions":"Cystic Fibrosis","enrollment":75},{"nctId":"NCT06302270","phase":"","title":"CFTR Modulators in Pregnancy and Postpartum","status":"RECRUITING","sponsor":"Region Stockholm","startDate":"2024-03-15","conditions":"Cystic Fibrosis","enrollment":75},{"nctId":"NCT03445793","phase":"","title":": TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2018-03-01","conditions":"Cystic Fibrosis (CF)","enrollment":5},{"nctId":"NCT04058366","phase":"PHASE3","title":"Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-12-05","conditions":"Cystic Fibrosis","enrollment":251},{"nctId":"NCT06184763","phase":"","title":"Evolution of the 6-minute Walk Test in Patients Treated With ELEXACAFTOR / TEZACAFTOR / IVACAFTOR","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2023-08-01","conditions":"Cystic Fibrosis","enrollment":73},{"nctId":"NCT05968612","phase":"PHASE1","title":"Bioequivalence and Food Effect Bioavailability Study of Lumacaftor Film-Coated Tablets","status":"COMPLETED","sponsor":"Qanatpharma Canada LTD","startDate":"2023-11-17","conditions":"Healthy Volunteer","enrollment":39},{"nctId":"NCT04415268","phase":"NA","title":"Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis","status":"WITHDRAWN","sponsor":"Universidad Europea de Madrid","startDate":"2020-06-09","conditions":"Cystic Fibrosis in Children","enrollment":""},{"nctId":"NCT04138589","phase":"","title":"Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2017-11-01","conditions":"Cystic Fibrosis in Children","enrollment":30},{"nctId":"NCT06072365","phase":"","title":"Treatment With Elexacaftor/Tezacaftor/Ivacaftor, in Patients With Cystic Fibrosis and Caloric Intake","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2021-10-21","conditions":"Cystic Fibrosis","enrollment":120},{"nctId":"NCT02565914","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-08","conditions":"Cystic Fibrosis","enrollment":1131},{"nctId":"NCT02725567","phase":"PHASE3","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-06-02","conditions":"Cystic Fibrosis","enrollment":57},{"nctId":"NCT04126473","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele","status":"COMPLETED","sponsor":"Eloxx Pharmaceuticals, Inc.","startDate":"2019-11-05","conditions":"Cystic Fibrosis","enrollment":17},{"nctId":"NCT04599465","phase":"PHASE3","title":"A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-15","conditions":"Cystic Fibrosis","enrollment":69},{"nctId":"NCT04362761","phase":"PHASE3","title":"A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-05-04","conditions":"Cystic Fibrosis","enrollment":172},{"nctId":"NCT05822102","phase":"","title":"Simultaneous quanTification of Elexacaftor/tezAcaftor/Ivacaftor Via Reverse Phase High Performance liquiD chromatographY","status":"UNKNOWN","sponsor":"National Jewish Health","startDate":"2023-02-09","conditions":"Cystic Fibrosis","enrollment":100},{"nctId":"NCT05111145","phase":"PHASE3","title":"A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-01-14","conditions":"Cystic Fibrosis","enrollment":86},{"nctId":"NCT05937815","phase":"NA","title":"Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2021-09-13","conditions":"Cystic Fibrosis","enrollment":253},{"nctId":"NCT04043806","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-08-09","conditions":"Cystic Fibrosis","enrollment":458},{"nctId":"NCT04537793","phase":"PHASE3","title":"Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-11-19","conditions":"Cystic Fibrosis","enrollment":83},{"nctId":"NCT04006873","phase":"PHASE2","title":"Gut Imaging for Function & Transit in Cystic Fibrosis Study 2","status":"COMPLETED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2019-09-03","conditions":"Cystic Fibrosis","enrollment":12},{"nctId":"NCT03912233","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-04-30","conditions":"Cystic Fibrosis","enrollment":87},{"nctId":"NCT05699148","phase":"","title":"Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior","status":"UNKNOWN","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2022-04-01","conditions":"Cystic Fibrosis","enrollment":17},{"nctId":"NCT05675592","phase":"","title":"Trikafta/Kaftrio and Pseudomonas Aeruginosa","status":"UNKNOWN","sponsor":"Ospedale San Raffaele","startDate":"2022-02-22","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT03601637","phase":"PHASE3","title":"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-09-07","conditions":"Cystic Fibrosis","enrollment":61},{"nctId":"NCT04135495","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele","status":"COMPLETED","sponsor":"Eloxx Pharmaceuticals, Inc.","startDate":"2019-11-25","conditions":"Cystic Fibrosis","enrollment":17},{"nctId":"NCT03625466","phase":"PHASE2","title":"A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-08-10","conditions":"Cystic Fibrosis","enrollment":51},{"nctId":"NCT05599230","phase":"","title":"Daily Monitoring of Respiratory Symptoms and Spirometry During ETI Treatment in Persons With Cystic Fibrosis.","status":"UNKNOWN","sponsor":"CHC Montlegia","startDate":"2022-09-01","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT05576324","phase":"","title":"Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-12-30","conditions":"Cystic Fibrosis","enrollment":130},{"nctId":"NCT05526027","phase":"NA","title":"Real-world Efficacy and Safety of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy in Adult Patients With Cystic Fibrosis (CF)","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-09-01","conditions":"Cystic Fibrosis","enrollment":85},{"nctId":"NCT04353817","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-06-19","conditions":"Cystic Fibrosis","enrollment":121},{"nctId":"NCT03768089","phase":"PHASE1, PHASE2","title":"Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-03-20","conditions":"Cystic Fibrosis","enrollment":115},{"nctId":"NCT03783286","phase":"","title":"Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2019-02-06","conditions":"Cystic Fibrosis","enrollment":15},{"nctId":"NCT03251911","phase":"PHASE4","title":"VX-770 for the Treatment of Chronic Bronchitis","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2020-01-01","conditions":"Chronic Bronchitis","enrollment":""},{"nctId":"NCT04066751","phase":"PHASE2","title":"The Multicenter Topic Trial","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2021-12-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT03447262","phase":"PHASE3","title":"A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-07-13","conditions":"Cystic Fibrosis","enrollment":484},{"nctId":"NCT03911713","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-04-17","conditions":"Cystic Fibrosis","enrollment":77},{"nctId":"NCT05200429","phase":"","title":"Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-11-01","conditions":"Cystic Fibrosis","enrollment":500},{"nctId":"NCT04923464","phase":"","title":"A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-06-30","conditions":"Cystic Fibrosis","enrollment":51},{"nctId":"NCT03227471","phase":"PHASE1, PHASE2","title":"A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-01-23","conditions":"Cystic Fibrosis","enrollment":225},{"nctId":"NCT04684823","phase":"NA","title":"The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2021-01-15","conditions":"Cystic Fibrosis, Adherence, Medication","enrollment":12},{"nctId":"NCT02871778","phase":"PHASE2","title":"Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia","status":"COMPLETED","sponsor":"Parion Sciences","startDate":"2016-08","conditions":"Primary Ciliary Dyskinesia","enrollment":123},{"nctId":"NCT03795363","phase":"","title":"Orkambi Treatment in 2 to 5 Year Old Children With CF","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2019-04-10","conditions":"Cystic Fibrosis","enrollment":28},{"nctId":"NCT03512119","phase":"","title":"Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-02-11","conditions":"Cystic Fibrosis Homozygous for Phe 508 Del CFTR, Glucose Intolerance or Newly Diagnosis Diabetes","enrollment":55},{"nctId":"NCT03691779","phase":"PHASE3","title":"Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-10-02","conditions":"Cystic Fibrosis","enrollment":71},{"nctId":"NCT04215796","phase":"NA","title":"Evaluation of the ReX-C System, in Patients Receiving CFTR Modulators for the Treatment of Cystic Fibrosis (CF).","status":"UNKNOWN","sponsor":"Dosentrx Ltd.","startDate":"2020-05-12","conditions":"Cystic Fibrosis, Adherence, Medication","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":204,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ivacaftor","Ivacaftor"],"phase":"phase_3","status":"active","brandName":"VX-770","genericName":"VX-770","companyName":"Vertex Pharmaceuticals Incorporated","companyId":"vertex-pharmaceuticals-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VX-770 is a CFTR potentiator that increases the opening probability and duration of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel at the cell surface. Used for Cystic fibrosis with G551D-CFTR mutation, Cystic fibrosis with other gating mutations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}